Research Topic

Pathophysiology and Pathogenic Mechanisms of Pulmonary Vascular Disease

About this Research Topic

Pulmonary arterial hypertension (PAH) is a progressive and fatal pulmonary vascular disease in which rising pulmonary vascular resistance (PVR) leads to increased pulmonary arterial pressure and right ventricular dysfunction. The major causes for elevated PVR include sustained pulmonary vasoconstriction, excessive pulmonary vascular remodeling, in situ thrombosis and increased vascular wall stiffness. Though a number of abnormally expressed genes and regulatory pathways contribute to increased PVR, little is known about the exact pathophysiology and pathogenic mechanisms which underlie the development of PAH and right heart failure.

The exact pathogenic mechanisms of PAH are complex and poorly understood, yet by combining human tissue or animal models with multi-omics studies as a means, a number of abnormally expressed genes and signaling pathways have been detected and confirmed, which will take research forward an important step. This Research Topic aims to collate articles related to the pathophysiology and pathogenesis of pulmonary vascular disease. The potential research topics focus on bio-markers of pulmonary vascular disease, diagnosis and treatment methods, and personalized therapeutic options. Therefore, we encourage investigators to engage in basic research and biomedical clinical practice to provide new insights on pulmonary vascular disease. Original research and review articles based on in animal models, in vitro and human studies as well as comprehensive reviews aiming to promote the research progress of the pathophysiology and pathogenesis of pulmonary vascular diseases.

Potential topics include but are not limited to the following:
• Translational research using human lung tissue and/or blood samples.
• In vivo experimental animal models of chronic pulmonary vascular disease induced by environmental exposures and/or drugs.
• In vitro cell culture models of chronic pulmonary vascular disease induced by environmental exposures and/or drugs.
• Based on the physiological functions of specific animals, a model for the treatment and prevention of chronic pulmonary vascular disease caused by environmental triggers (e.g., hypoxia) or drugs.
• Identification and characterization of novel regulatory pathways that link environmental exposures and drugs with pulmonary vascular disease.
• Identification of the correlation between coding RNA and/or non-coding RNA with pulmonary vascular disease.
• Identification of biomolecules, enzymes and metabolites of pulmonary vascular disease as epigenetic and epi-transcriptional regulators.
• Novel therapeutic approaches, pre-clinical and clinical trials for PH: from bench to bedside.
• Clinical registry data including novel phenotypes, risk stratification tools, and patient centered observations.

Topic Editor Dr. Ankit Desai holds patents related to treatment and prevention of pulmonary hypertension and to diagnosis and treatment of arrhythmias. All other Topic Editors declare no potential conflicts of interest with regard to the Research Topic subject.


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Pulmonary arterial hypertension (PAH) is a progressive and fatal pulmonary vascular disease in which rising pulmonary vascular resistance (PVR) leads to increased pulmonary arterial pressure and right ventricular dysfunction. The major causes for elevated PVR include sustained pulmonary vasoconstriction, excessive pulmonary vascular remodeling, in situ thrombosis and increased vascular wall stiffness. Though a number of abnormally expressed genes and regulatory pathways contribute to increased PVR, little is known about the exact pathophysiology and pathogenic mechanisms which underlie the development of PAH and right heart failure.

The exact pathogenic mechanisms of PAH are complex and poorly understood, yet by combining human tissue or animal models with multi-omics studies as a means, a number of abnormally expressed genes and signaling pathways have been detected and confirmed, which will take research forward an important step. This Research Topic aims to collate articles related to the pathophysiology and pathogenesis of pulmonary vascular disease. The potential research topics focus on bio-markers of pulmonary vascular disease, diagnosis and treatment methods, and personalized therapeutic options. Therefore, we encourage investigators to engage in basic research and biomedical clinical practice to provide new insights on pulmonary vascular disease. Original research and review articles based on in animal models, in vitro and human studies as well as comprehensive reviews aiming to promote the research progress of the pathophysiology and pathogenesis of pulmonary vascular diseases.

Potential topics include but are not limited to the following:
• Translational research using human lung tissue and/or blood samples.
• In vivo experimental animal models of chronic pulmonary vascular disease induced by environmental exposures and/or drugs.
• In vitro cell culture models of chronic pulmonary vascular disease induced by environmental exposures and/or drugs.
• Based on the physiological functions of specific animals, a model for the treatment and prevention of chronic pulmonary vascular disease caused by environmental triggers (e.g., hypoxia) or drugs.
• Identification and characterization of novel regulatory pathways that link environmental exposures and drugs with pulmonary vascular disease.
• Identification of the correlation between coding RNA and/or non-coding RNA with pulmonary vascular disease.
• Identification of biomolecules, enzymes and metabolites of pulmonary vascular disease as epigenetic and epi-transcriptional regulators.
• Novel therapeutic approaches, pre-clinical and clinical trials for PH: from bench to bedside.
• Clinical registry data including novel phenotypes, risk stratification tools, and patient centered observations.

Topic Editor Dr. Ankit Desai holds patents related to treatment and prevention of pulmonary hypertension and to diagnosis and treatment of arrhythmias. All other Topic Editors declare no potential conflicts of interest with regard to the Research Topic subject.


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

20 January 2021 Abstract
20 April 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

20 January 2021 Abstract
20 April 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..